Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.
about
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repairPrevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesNew anticoagulants for the prevention and treatment of venous thromboembolismPostoperative management of hip fractures: interventions associated with improved outcomesReview of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgeryBest practices for elderly hip fracture patients. A systematic overview of the evidence.Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing.Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation.Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy.Pentasaccharides for the prevention of venous thromboembolism.Symptomatic venous thromboembolism following a hip fracture.Pathways for venous thromboembolic prophylaxis in medical and surgical patients.Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.Review article: Anti-embolism stockings.Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.Is there adequate provision of venous thromboembolism prophylaxis following hip arthroplasty? An audit and international surveyLittle impact of antiplatelet agents on venous thromboembolism after hip fracture surgery.Challenges in the prevention of venous thromboembolism in the elderly.Evidence for extended prophylaxis in the setting of orthopedic surgery.Assessment of the risk and the prophylaxis of venous thromboembolism in surgical patients.Rationale for the use of antifactor Xa in the treatment and prevention of venous and arterial thromboembolic events.Fondaparinux: an update on new study results.New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinPost-discharge symptomatic thromboembolic events in hip fracture patientsLow dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study.Short- and long-acting synthetic pentasaccharides as antithrombotic agents.New trends in anticoagulant treatments.Anticoagulation via anti-Factor Xa inhibition.Extended duration of thromboprophylaxis in acutely ill medical patients: optimizing therapy?Evidence for the prevention of venous thromboembolism.Venous thromboembolism prevention post neck of femur fractures - does it make a difference?Evidence-based guide to perioperative medicine.Community nurse resource implications for a change in heparin prophylaxis policy.Enoxaparin and rivaroxaban have different effects on human mesenchymal stromal cells in the early stages of bone healingFondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients.Outpatient-based primary and secondary thromboprophylaxis with low-molecular-weight heparin.Lower limb contrast venography: a modified technique for use in thromboprophylaxis clinical trials for the accurate evaluation of deep vein thrombosis.
P2860
Q24185998-9A031096-F4FF-44CB-A834-A4EDDD7B1713Q24632872-09F37581-003E-46E6-B37C-789E49949B14Q24681351-06257AAB-32BA-4DA9-AA36-8DD5235F0A22Q26830646-BB42A4D5-DFA1-4268-8917-5AE58869FC3BQ28219412-D5C90D4C-D5FC-44C2-B09C-DDF1899DB95BQ30477531-5D3571F3-FA93-49DE-BFB2-3D7E8C72875CQ33362184-8A54F63D-4D0D-4D02-BE45-160B5488DAB8Q33372266-45946B8D-1683-46A5-81B2-2E9CF507A459Q33389966-AEF8CDB0-86B6-4D8F-A6F3-4C229945B884Q33396864-15096917-D5C8-4466-A032-8BD7B529DB52Q33419371-C493AF53-EC3E-4291-B162-22FDE97D199DQ33436419-6F6187F6-D539-400C-A029-D503F0869472Q33660791-8F56834A-17CD-4789-BE64-161AFCDEE780Q34264223-0C4991DF-041F-4E83-A17F-90473AD7200DQ34549913-1429A465-109D-463B-8A14-23F931E73ABCQ34959822-E38AEE63-8BE9-43F5-B448-FF3E02A552D5Q35075041-C70D181D-FAD0-466B-95D8-660AD47F08DAQ35562634-4A8CD49A-7EEB-4D47-BFC6-9025598A5008Q35588756-AEE7ADDF-D2F7-4ED8-9E9B-89B1851BA5C7Q35590654-75E95728-8AA9-4125-ABE8-0C54B9F6F9A4Q35860195-54D95910-D364-4C16-A5CB-1F624E46ABD3Q35866089-DF06AB11-287F-4831-942A-7EF8A8307742Q36030498-A519E906-EA3D-448B-B157-C8B5692E44BEQ36034733-16FCE9ED-013A-4C5C-BA1A-FB393DB96DE8Q36034740-3EB83B2D-D7D1-41A9-9014-0A734D2038C2Q36042279-334F9158-32ED-4E30-852C-0BBAA806430CQ36102731-10E97550-A8DE-467B-9283-AD8573E6BD8CQ36131612-3CA58E6D-06A7-472F-9523-4AFE0B85BC30Q36196467-059AD1E8-D77D-4545-921D-F9F25DC2081BQ36283533-8DA6C9A5-ECC0-43B7-A8C7-C2FE3AC975C6Q36458159-49406F30-AD00-4362-9180-4F8BAF0513C6Q36632271-3E0465C5-2C4D-492F-A4AA-6720CC35E323Q36640841-0FBF247A-7759-4CE8-A3DB-57CEB89BF7A8Q36749497-76B08F71-3A0C-4E39-88E3-63073C5D661DQ36834437-49474101-B94F-409D-BE88-ED76773D2554Q36847834-4778812D-B58C-4044-9E32-C07F29E55727Q36857020-FB966B64-2C9F-453D-A092-FEF33F4BCE5CQ36867390-AF13B98E-904E-4F59-A8D1-D56AB9DFF0D8Q36951531-970984DD-8A4D-4B2B-8609-D79B1F2F8C78Q36957164-A1990356-85AE-43E0-88AE-D482F527AA2D
P2860
Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Duration of prophylaxis agains ...... ontrolled, double-blind study.
@en
Duration of prophylaxis agains ...... ontrolled, double-blind study.
@nl
type
label
Duration of prophylaxis agains ...... ontrolled, double-blind study.
@en
Duration of prophylaxis agains ...... ontrolled, double-blind study.
@nl
prefLabel
Duration of prophylaxis agains ...... ontrolled, double-blind study.
@en
Duration of prophylaxis agains ...... ontrolled, double-blind study.
@nl
P2093
P1476
Duration of prophylaxis agains ...... ontrolled, double-blind study.
@en
P2093
Bengt I Eriksson
Michael R Lassen
PENTasaccharide in HIp-FRActure Surgery Plus Investigators
P304
P356
10.1001/ARCHINTE.163.11.1337
P407
P577
2003-06-01T00:00:00Z